StockNews.com started coverage on shares of Zogenix (NASDAQ:ZGNX – Get Rating) in a report issued on Sunday. The firm issued a hold rating on the stock. A number of other research firms have also weighed in on ZGNX. Zacks Investment Research raised shares of Zogenix from a hold rating to a buy rating and set […]
This randomized clinical trial compares the efficacy and adverse effects of the 3 most frequently prescribed corticosteroid regimens for boys with Duchenne musc
FINTEPLA® has demonstrated efficacy in the most difficult-to-treat seizure types,1,2 including drop seizures, which cause a person to suddenly lose muscle.